Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Odanacatib: Phase IIb data

In a double-blind Phase IIb in 399 postmenopausal women with low BMD, the 3 higher doses of odanacatib met the primary

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE